CIK 0001662774
- Non-accelerated filer
- Smaller reporting company
IRulya Therapeutics Inc.
Sign in to watch- Ticker
- IRLA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 901024039
- Phone
- +1 203-208-8994
- Business address
- 101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
- Former names
- Quince Therapeutics, Inc., Cortexyme, Inc.
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy CEO AND CHIEF MEDICAL OFFICER bought 154,500 shares at an average $0.69 ($107,375)
- 4 Open-market buy PRESIDENT bought 48,387 shares at $0.65 ($31,452)
- 4 Open-market buy CHIEF BUSINESS OFFICER AND COO bought 38,924 shares at an average $0.62 ($24,166)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Exercise or conversion CHIEF BUSINESS OFFICER AND COO acquired 56,061 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Exercise or conversion CHIEF EXECUTIVE OFFICER acquired 240,530 shares (option exercise)
Page 3 of 11 · 211 filings